Real-World Treatment Patterns and Effectiveness of Targeted and Immune Checkpoint Inhibitor-Based Systemic Therapy in BRAF Mutation-Positive NSCLC

Real-World Treatment Patterns and Effectiveness of Targeted and Immune Checkpoint Inhibitor-Based Systemic Therapy in BRAF Mutation-Positive NSCLC

Introduction: BRAF mutations (present in 2%–3% of NSCLC) are a known oncogenic driver and emerging therapeutic target. There is a scarcity of real-world data describing the clinical characteristics, treatment patterns, and effectiveness of targeted BRAF-inhibiting and immune checkpoint inhibitor (IC...

Full description

Bibliographic Details
Main Authors: Amanda J.W. Gibson, BSc (Hons), Aliyah Pabani, MD, Michelle L. Dean, BSc, Guillermo Martos, MD, Winson Y. Cheung, MD, MPH, FRCPC, Vishal Navani, M.B.B.S., MRCP, FRACP
Format: Article
Language:English
Published: Elsevier 2023-03-01
Series:JTO Clinical and Research Reports
Subjects:
BRAF
Immune checkpoint inhibitor
Targeted therapy
Outcomes
Real-world
Online Access:http://www.sciencedirect.com/science/article/pii/S2666364322001850

Internet

http://www.sciencedirect.com/science/article/pii/S2666364322001850

Similar Items